Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Mobility loss rarely shows up as one big event. For most older adults, it arrives in small, compounding changes — a shorter stride, a slower sit-to-stand, a little more hesitation stepping off a curb — until independence starts to feel less guaranteed. What’s changed in recent years is how rehab responds. Instead of generic “stay […]

The post Evidence-Based Rehabilitation Strategies for Long-Term Mobility appeared first on Medical News Bulletin.

Children wearing SightGlass Vision Diffusion Optics Technology lenses had no increase in astigmatism compared with children wearing control lenses, according to studies presented at the Netherlands Contact Lens Congress.
The study was conducted after other research suggested that astigmatism could increase with the use of peripheral defocus, the myopia control method used by MyoVision (Zeiss) and Essilor Stellest (EssilorLuxottica). SightGlass Diffusion Optics Technology (DOT) lenses work through a different mechanism: contrast modulation.
“It’s important that it’s just one study, and I don’t

The FDA has approved the combination of nivolumab plus chemotherapy as first-line treatment for certain patients with stage III or IV classical Hodgkin lymphoma.
The approval, for individuals aged 12 years and older, is based on results from randomized trial data that showed nivolumab (Opdivo, Bristol Myers Squibb) plus doxorubicin, vinblastine and dacarbazine (AVD) improved PFS 58% compared with brentuximab vedotin (Adcetris, Seagen) plus AVD.
Healio previously reported on the phase 3 SWOG S1826 trial, which included 994 patients randomly assigned to receive either the nivolumab or brentuximab

Year-to-year exposure to elevated blood pressure from age 30 to 40 years was linked to increased risk for heart disease and kidney events among Korean adults, a speaker reported.
A study evaluating the impact of exposure to BP above 120 mm Hg from ages 30 to 40 years on CVD and chronic kidney disease (CKD) was presented at the American Heart Association EPI | Lifestyle Scientific Sessions.
“Young adults often have a very low predicted 10-year risk of heart disease, even when they have elevated or high blood pressure (a systolic blood pressure measure of 120 mm Hg or higher, or a diastolic blood

Antibiotics have an enduring impact on the gut microbiome, causing disturbances that can last up to 8 years, according to a study of nearly 15,000 people published in Nature Medicine.
The greatest disruptions to gut species occurred within 1 year of consuming antibiotics, but some disruptions can last much longer, the researchers found. Use of some antibiotics altered the microbiome by 10% to 15% in the 4 to 8 years after treatment.
“Our study provides the strongest evidence so far of these effects and gives clinicians a reference when addressing patient concerns,” Gabriel Baldanzi,

The American Association for the Study of Liver Diseases supports a court ruling that temporarily blocks changing the childhood and adolescent immunization schedule, including the hepatitis B birth and childhood hepatitis A vaccinations.
The ruling, made by U.S. District Judge Brian E. Murphy on March 16, halted the Trump administration’s modifications to the CDC’s evidence-based childhood vaccine schedule.
Those changes include no longer recommending universal HBV birth dose and routine HAV vaccination for infants and children, respectively, but instead only recommending them for

The FDA has approved an expanded indication for setmelanotide to treat children and adults with acquired hypothalamic obesity, Rhythm Pharmaceuticals announced.
Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is a melanocortin-4 receptor agonist that was previously approved by the FDA to treat children and adults with obesity due to Bardet-Biedl syndrome, genetically confirmed pro-opiomelanocortin (POMC)/proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency or leptin receptor (LEPR) deficiency. The newest FDA-approved indication will allow the drug to be prescribed for children and

Representatives from the National Eczema Association recently met with policymakers on Capitol Hill to discuss stalled step therapy legislation, prior authorization burdens and federal research funding needs.
During a congressional briefing held Feb. 24, National Eczema Association (NEA) advocates presented data from their 2025 survey that showed continued insurance-related treatment delays for people with eczema.
According to the survey, nearly 40% of patients with eczema and their caregivers experienced at least one insurance coverage issue in the past year, 12% had to discontinue a

My New York City practice has been a refractive-only practice for more than 25 years, offering the full range of FDA-approved vision correction surgery options, from lasers to IOLs.
The rate-limiting factors for presbyopia-correcting IOLs, in my opinion, have long been dysphotopsias and enhancements. When I first started implanting presbyopia-correcting IOLs, the side effect profile — primarily problems with night vision — was significant, and achieving good vision at all distances was challenging. Early on, I explanted about 4% to 5% of the multifocal IOLs I implanted and performed laser

Retained lens fragments are a frustrating complication that can challenge even the most meticulous cataract surgeon.
While modern phacoemulsification has made the procedure remarkably efficient, the high-energy ultrasonic fragmentation of the nucleus inherently creates nuclear chips. These small pieces of nuclear material can migrate into the deep recesses of the anterior segment. If left behind, these fragments can lead to chronic inflammation, localized corneal edema, which is classically at the inferior limbus, and sometimes secondary glaucoma. To minimize this risk, a surgeon must